Newsroom

Sight Sciences Files Lawsuit Against Ivantis for Patent Infringement

Sight Sciences Seeks Injunction Related to Hydrus® Microstent’s Infringement

read more +
Sight Sciences to Participate in the Morgan Stanley Global Healthcare Conference

MENLO PARK, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address the underlying...

read more +
Sight Sciences Announces Publication of Favorable Two-Year Outcomes of Standalone Use of the OMNI® Surgical System in Mild to Moderate Open-Angle Glaucoma

Pioneering the Development of the Standalone MIGS Market, this Real-world data published in Clinical Ophthalmology show the safety, efficacy, and durability of effect of OMNI for use in a standalone procedure to reduce intraocular pressure and medication burden

read more +
Sight Sciences Reports Second Quarter 2021 Financial Results

MENLO PARK, Calif., August 12, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and...

read more +
Sight Sciences to Report Second Quarter 2021 Financial Results on August 12, 2021

MENLO PARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) today announced it will report financial results for the second quarter 2021 after the market close...

read more +
Sight Sciences Announces Pricing of Initial Public Offering

Sight Sciences Announces Pricing of Initial Public Offering

read more +
Sight Sciences Announces Substantial Crossover Raise

Funds will be used to continue clinical and commercial acceleration

read more +
Sight Sciences Announces Positive Interim Clinical Results from Prospective, Multicenter Trial of the OMNI Surgical System in Open Angle Glaucoma

Data presented at the Women in Ophthalmology 2020 Virtual Summer Symposium

read more +